Loading…

Chemours Co.CCCompetitor analysis, valuation and peers

United States · USD·Materials›Chemicals: Specialty

Makes fluoroproducts (refrigerants, Teflon) and titanium dioxide pigments for industrial and consumer applications, spun off from DuPont.

Momentum weak 20
Mkt cap
$1.92B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$33.9M
20-day average traded
Fwd P/E
8.2×
forward earnings
ROIC−WACC
-3.6 pp
WACC 7.6%
Hurdle
+13 pp
Req g minus delivered
Official | Implied
BB- / B+
agencies · bond market
Next earnings
97 days
11 Feb 2027
Close · USD$12.75
1D0.0%
1W-5.8%
1M-7.8%
3M-12.6%
6M-44.7%
YTD+8.1%
1Y+5.8%
ATR %5.1%
Beta1.42
52w lowhigh55.5% off high

What Chemours does

Makes fluoroproducts (refrigerants, Teflon) and titanium dioxide pigments for industrial and consumer applications, spun off from DuPont.

Titanium dioxide, a white pigment used in paint and plastics, is sold at prices that rise and fall with supply, while refrigerants and fluoropolymers are more specialised and protected by patents on newer low-warming refrigerants. Legacy PFAS (so-called forever chemicals) liabilities are shared with DuPont and Corteva under a 2021 cost-sharing agreement.

Products and services

  • Titanium dioxide (Ti-Pure pigments)
  • Fluoroproducts (Opteon refrigerants, Teflon)
  • Thermal & Specialized Solutions

Customers

  • Paint/coatings manufacturers
  • HVAC/refrigeration equipment makers
  • Industrial manufacturers

Where it sits in the supply chain

  • Materials
  • Chemicals: Specialty
  • Fluoroproducts and titanium dioxide

What could go right

  • Global HVAC refrigerant transition under low-GWP regulations
  • TiO2 price cycle recovery

What could go wrong

  • PFAS litigation and remediation liabilities
  • TiO2/commodity chemical price cyclicality

Moat: narrow (IP / patents, scale, process know-how). Large-scale TiO2 and fluorochemical production with patented low-GWP refrigerant technology, though facing PFAS litigation liability.

Headquarters: Wilmington, Delaware, US · Founded: 2015 · Employees: 5,700

Named competitors

Chemours at a glance

Size Chemours (CC) is a United States Materials company (Chemicals: Specialty) with a market value of $1.92B, the 1823rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $12.75 on 6 Nov 2026.

Performance Over six months the shares fell 44.7%, against -24.6% for the median peer and -1.1% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue fell 0.5% over the last twelve months (peer median +18.1%); the operating margin is 3.0% (peer median 7.6%).

Valuation It trades at 8.2× forward earnings against a peer median of 16.1× (2nd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.6 points below its cost of capital (7.6% WACC).

Backlog Backlog (remaining performance obligations) was $98.0M at 30 Sep 2026, down 46% on a year earlier — 0.0 years of trailing revenue. Backlog detail →

Credit Chemours has 3 bonds outstanding ($1.81B), rated BB- by the agencies and trading like B+ at a weighted spread of 276 bp.

Short interest Short interest is 9.9% of the free float (15 Oct 2026).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010011 May 202611 Aug 20266 Nov 2026Peer median 73CC 50
Six months, rebased to 100: Chemours against the median of its 20 peers (local-currency closes).

Chemours financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$5.84B$5.81B$5.78B$6.08B$6.79B
Revenue growth—0%-5%-11%—
Gross profit$882M$901M$1.14B$1.31B$1.64B
EBITDA$492M$654M$735M$812M$1.10B
Net income-$168M-$386M$69.0M-$238M$578M
Free cash flow$211M$51.0M-$993M$186M$447M
Capital expenditure$189M$213M$360M$370M$307M
Total debt$4.03B$4.39B$4.37B$4.30B$3.88B

Quarterly statements and history in the cockpit →

Chemours competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%688268MTX6038230022504208GRWRHITECHVBK00136900240800201030121960390601894368011790603938CC6-month return →1-month return →
Up and to the right = strong over both horizons. Chemours is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×100×200×688268MTX6038230022504208GRWRHITECHVBK002408002010301219603906688005300655601568CCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chemours is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688268MTX603823002250GRWRHITECHVBK00240801894368601568CCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chemours is the large dot.

Chemours competitors and peer comparison

Head to head with its named competitors (CC vs TROX vs HON vs KRO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Chemours CC$1.92B-45%-1%3%8.2×16.1%
Tronox TROX$401M-72%+4%-3%n/an/a
Honeywell Technologies HON$69.8B-1%-17%18%23.2×4.1%
Kronos Worldwide KRO$859M+46%+3%-1%11.9×17.6%

How Chemours compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chemours against its 20 peers (data as of 6 Nov 2026)
MeasureCCPeer medianRank in peer set
1-month return-7.8%-13.3%8th highest of 21
6-month return-44.7%-24.6%6th lowest of 20
Distance from 52-week high-55.5%-49.8%8th lowest of 21
Revenue growth (TTM)-0.5%+18.1%3rd lowest of 20
Operating margin3.0%7.6%6th lowest of 21
Forward P/E8.2×16.1×2nd cheapest of 18
Growth the price implies (Req g, 7 yrs)16.1%6.0%4th most demanding of 11
Growth delivered (Del g)+3.2%+6.4%4th lowest of 11
Hurdle (Req g minus delivered)+12.9 pp+0.0 pp5th most demanding of 11
ROIC minus cost of capital-3.6 pp-0.2 pp5th lowest of 21
EV / EBITDA10.6×10.9×4th cheapest of 8
Net debt / EBITDA6.7×-1.0×most indebted of 8
Bond spread276 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Chemours CCUnited States$1.92B-45%-1%3%8.2×16.1%+3.2%
Guangdong Huate Gas 688268.SSChina$1.92B-47%+27%13%56.1×35.6%+7.2%
Minerals Technologies MTXUnited States$1.91B-22%+5%13%9.8×0.5%+5.4%
Lily 603823.SSChina$1.91B+85%+2%10%58.1×27.9%+1.4%
Standard Nuclear STDNUnited States$1.90Bn/an/a-288%n/an/an/a
Lianhe Chemical Technology 002250.SZChina$1.90B-16%+28%13%19.7×-3.4%+6.1%
Ube 4208.TJapan$1.94B+33%+3%4%12.0×n/an/a
Garware Hi-Tech Films GRWRHITECH.NSIndia$1.88B+40%+15%21%37.7×38.8%+16.6%
Verbio VBK.DEGermany$1.88B-37%+19%5%13.2×1.1%+12.8%
Inner Mongolia Shuangxin Environment-Friendly Material 001369.SZChina$1.87B-28%+3%15%n/an/an/a
Zibo Qixiang Tengda Chemical 002408.SZChina$1.87B-33%+18%-1%220.0×3.7%-0.8%
Transfar Zhilian 002010.SZChina$1.87B-21%-30%5%16.1×n/an/a
Ganzhou Teng Yuan Cobalt New Material 301219.SZChina$1.85B-53%+64%10%12.5×n/an/a
Jiangsu Lopal Tech 603906.SSChina$1.82B-54%+96%7%14.7×n/an/a
Dongyue 0189.HKHong Kong$2.04B-28%+8%19%5.6×-12.4%+6.6%
Ningbo Ronbay New Energy Technology 688005.SSChina$2.05B-45%+41%1%37.8×n/an/a
Fuso Chemical 4368.TJapan$1.79B-19%+17%26%13.1×8.4%+12.8%
Crystal Clear Electronic Material 300655.SZChina$1.75B-25%+27%7%78.2×n/an/a
Shaanxi Beiyuan Chemical Industry 601568.SSChina$2.11B-9%-8%-4%11.8×11.8%-1.8%
SKC 011790.KSSouth Korea$2.14B-46%+24%-9%n/an/an/a
Tangshan SunFar Silicon Industries 603938.SSChina$1.72B+6%+30%8%42.8×n/an/a

Chemours bonds and credit

Chemours has 3 bonds outstanding with $1.81B face value. The agencies rate it BB-; its bonds trade like B+. Weighted yield 7.46%, a spread of 276 bp over government bonds.

Every bond, yield and spread in the cockpit →

Chemours backlog

Chemours reported $98.0M of remaining performance obligations at 30 Sep 2026, down 46% from a year earlier and down 20% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 0.98.

Questions

Who are Chemours's main competitors?
Named competitors: Tronox (TROX), Honeywell (Solstice refrigerants) (HON), Kronos Worldwide (KRO). The cockpit's measured peer set (industry) also includes Guangdong Huate Gas (688268.SS), Minerals Technologies (MTX), Lily (603823.SS), Standard Nuclear (STDN), Lianhe Chemical Technology (002250.SZ), Ube (4208.T).
Is Chemours expensive compared with its peers?
On forward p/e it trades at 8.2× against a peer median of 16.1×, 2nd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Chemours stock performed?
Over six months to 6 Nov 2026 the shares returned -44.7% against -24.6% for the median peer; over one year +5.8%.
What is Chemours's backlog?
Chemours's remaining performance obligations (contracted revenue not yet recognised) were $98.0M at 30 Sep 2026, -46% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.